Neuromeka Announces 122.6 Billion Won Rights Offering with 25.76% Dilution, Proceeds for Pohang Factory and Working Capital


  • Neuromeka plans to raise approximately 122.6 billion KRW through a rights offering of 3,196,465 new shares (25.76% dilution) at 38,350 KRW per share. The proceeds will be used for 76 billion KRW in facility investment for the new Pohang factory, 36.6 billion KRW for working capital including raw materials and labor, and 10 billion KRW for short-term debt repayment.
  • The offering will dilute existing shareholders' equity by over 25%, with the largest shareholder CEO Park Jong-hoon planning to subscribe only 15% of his allotment, reducing his stake from 18% to around 14%. Additional dilution may occur from remaining convertible bonds and stock options after the capital increase.
  • The main use of funds is the construction of a new factory in Pohang, scheduled to start in Q3 2026 and complete by Q2 2028, aimed at expanding production capacity for collaborative robots and humanoids and improving cost competitiveness. However, increased fixed costs and uncertain revenue performance pose risks to profitability.
  • Neuromeka reported 2025 consolidated revenue of 19 billion KRW and operating loss of 14.9 billion KRW, marking three consecutive years of losses. The debt ratio improved from 557.63% at end-2025 to 101.14% in Q1 2026, and is expected to drop to 19.30% after the rights offering. However, continued operating losses could again strain financial stability.
  • A concurrent 0.5 bonus share per existing share will be distributed, including to new shares from the rights offering, described as a shareholder-friendly measure. While increasing liquidity, it does not add fundamental value.
  • [AI Summary]Neuromeka's massive rights offering causes severe 25.76% dilution, with the largest shareholder's low participation raising governance concerns. Funds are allocated for growth investments, but past performance gaps and persistent operating losses create uncertainty. The balance sheet improves temporarily, but without sustainable profitability, long-term shareholder value may be eroded.

KOSDAQ Filing Information


  • Prospectus
  • Company: Neuromeka (348340)
  • Submission: Neuromeka Co., Ltd.

  • Shares: 12,409,151
  • Price: 48,600 KRW
  • Market Cap: 603.1 B KRW